Cellectar Biosciences Inc
CLRB5.010USD
+0.290+6.14%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
7.70MCap. mercado
PérdidaP/E TTM
Más Datos de Cellectar Biosciences Inc Compañía
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).
Información de la empresa
Símbolo de cotizaciónCLRB
Nombre de la empresaCellectar Biosciences Inc
Fecha de salida a bolsaMay 20, 2005
Director ejecutivoMr. James V. Caruso
Número de empleados11
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 20
Dirección100 Campus Drive
CiudadFLORHAM PARK
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal07932
Teléfono16084418120
Sitio Webhttps://www.cellectar.com/
Símbolo de cotizaciónCLRB
Fecha de salida a bolsaMay 20, 2005
Director ejecutivoMr. James V. Caruso
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jarrod Longcor
Mr. Jarrod Longcor
Chief Operating Officer
Chief Operating Officer
12.77K
+360.88%
Mr. James V. Caruso
Mr. James V. Caruso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.64K
+609.38%
Mr. Chad J. Kolean
Mr. Chad J. Kolean
Chief Financial Officer, Vice President, Secretary
Chief Financial Officer, Vice President, Secretary
6.42K
+352.36%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Independent Chairman of the Board
Independent Chairman of the Board
83.00
--
Mr. Stefan D. Loren, Ph.D.
Mr. Stefan D. Loren, Ph.D.
Independent Director
Independent Director
--
--
Mr. Frederick W. (Fred) Driscoll
Mr. Frederick W. (Fred) Driscoll
Independent Director
Independent Director
--
--
Mr. John P. Neis
Mr. John P. Neis
Independent Director
Independent Director
--
--
Dr. Asher Alban Chanan-Khan, M.D.
Dr. Asher Alban Chanan-Khan, M.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jarrod Longcor
Mr. Jarrod Longcor
Chief Operating Officer
Chief Operating Officer
12.77K
+360.88%
Mr. James V. Caruso
Mr. James V. Caruso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.64K
+609.38%
Mr. Chad J. Kolean
Mr. Chad J. Kolean
Chief Financial Officer, Vice President, Secretary
Chief Financial Officer, Vice President, Secretary
6.42K
+352.36%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Independent Chairman of the Board
Independent Chairman of the Board
83.00
--
Mr. Stefan D. Loren, Ph.D.
Mr. Stefan D. Loren, Ph.D.
Independent Director
Independent Director
--
--
Mr. Frederick W. (Fred) Driscoll
Mr. Frederick W. (Fred) Driscoll
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 26 de jul
Actualizado: sáb., 26 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
2.14%
UBS Financial Services, Inc.
1.11%
Adar1 Capital Management LLC
0.68%
Lytton (Laurence W)
0.63%
Geode Capital Management, L.L.C.
0.55%
Other
94.88%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
2.14%
UBS Financial Services, Inc.
1.11%
Adar1 Capital Management LLC
0.68%
Lytton (Laurence W)
0.63%
Geode Capital Management, L.L.C.
0.55%
Other
94.88%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
3.70%
Individual Investor
1.91%
Investment Advisor/Hedge Fund
1.28%
Hedge Fund
1.21%
Corporation
0.36%
Research Firm
0.23%
Venture Capital
0.13%
Bank and Trust
0.03%
Other
91.15%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
84
202.41K
7.72%
-340.14K
2025Q1
86
199.12K
11.22%
-346.61K
2024Q4
85
5.89M
13.20%
-10.24M
2024Q3
82
15.21M
37.53%
+860.01K
2024Q2
87
12.77M
37.42%
+1.31M
2024Q1
84
10.31M
32.95%
-1.69M
2023Q4
71
9.17M
43.97%
+2.46M
2023Q3
74
3.14M
32.62%
+389.97K
2023Q2
83
3.71M
38.83%
+394.07K
2023Q1
91
3.81M
40.21%
+165.83K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
57.40K
2.14%
-172.00
-0.30%
Mar 31, 2025
UBS Financial Services, Inc.
29.84K
1.11%
+17.42K
+140.12%
Mar 31, 2025
Adar1 Capital Management LLC
18.19K
0.68%
+16.85K
+1256.45%
Apr 17, 2025
Lytton (Laurence W)
16.78K
0.63%
--
--
Apr 17, 2025
Geode Capital Management, L.L.C.
14.78K
0.55%
+3.08K
+26.38%
Mar 31, 2025
Longcor (Jarrod)
2.77K
0.18%
+1.00K
+56.47%
Apr 17, 2025
Squarepoint Capital LLP
12.36K
0.46%
-4.98K
-28.71%
Mar 31, 2025
Caruso (James V)
1.64K
0.11%
--
--
Apr 17, 2025
Citadel Advisors LLC
11.44K
0.43%
+11.44K
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proporción0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Fecha
Tipo
Relación
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
